Literature DB >> 2078420

In vitro inhibition of HIV-1 infectivity by human salivas.

D W Archibald1, G A Cole.   

Abstract

Inhibitory factors to human immunodeficiency virus type 1 (HIV-1) in saliva may be responsible for the infrequent isolation of virus from saliva and also may account for the marked infrequency of salivary and/or oral transmission of HIV-1. Incubation of HIV-1 with human saliva followed by addition of the mixture to susceptible cells leads to partial or complete suppression of viral replication in vitro. We investigated the inhibitory effects of whole saliva and specific glandular salivas on HIV-1 infectivity as measured by viral-induced cytopathic effects in susceptible cells. Whole saliva contained marked inhibitory activity to HIV-1, strain HTLV-IIIB, and to virus infected cells. Submandibular saliva contained inhibitory activity, but of lesser quantity. Parotid saliva demonstrated no HIV-inhibitory activity. Whole saliva also appeared to contain filterable components that were inhibitory to lymphocyte growth. Passage through a .45 micron pore-size filter eliminated the viral inhibitory activity of submandibular saliva and some of the activity in whole saliva. All salivas except parotid incubated with HIV-1 followed by filtration were inhibitory suggesting that complexing of virus with high molecular weight, submandibular mucins may play a role in viral inhibition.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2078420     DOI: 10.1089/aid.1990.6.1425

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  21 in total

Review 1.  Antiviral activities in human saliva.

Authors:  D Malamud; W R Abrams; C A Barber; D Weissman; M Rehtanz; E Golub
Journal:  Adv Dent Res       Date:  2011-04

Review 2.  Positive and negative aspects of the human immunodeficiency virus protease: development of inhibitors versus its role in AIDS pathogenesis.

Authors:  K Ikuta; S Suzuki; H Horikoshi; T Mukai; R B Luftig
Journal:  Microbiol Mol Biol Rev       Date:  2000-12       Impact factor: 11.056

3.  Enhanced secretory leukocyte protease inhibitor in human immunodeficiency virus type 1-infected patients.

Authors:  A A Baqui; T F Meiller; W A Falkler
Journal:  Clin Diagn Lab Immunol       Date:  1999-11

4.  HIV shedding in the oral cavity: an assessment of HIV type, immunovirologic, demographic and oral factors.

Authors:  Patricia B Pavlinac; Stephen E Hawes; Geoffrey S Gottlieb; Awa Gaye; Charlotte F N'Diaye; Cathy W Critchlow; Papa Salif Sow; Qinghua Feng; Nancy B Kiviat
Journal:  Sex Transm Infect       Date:  2012-02       Impact factor: 3.519

Review 5.  Pathogenesis of human immunodeficiency virus infection.

Authors:  J A Levy
Journal:  Microbiol Rev       Date:  1993-03

Review 6.  The oral mucosa immune environment and oral transmission of HIV/SIV.

Authors:  Lianna F Wood; Ann Chahroudi; Hui-Ling Chen; Heather B Jaspan; Donald L Sodora
Journal:  Immunol Rev       Date:  2013-07       Impact factor: 12.988

7.  Secretory leukocyte protease inhibitor: a human saliva protein exhibiting anti-human immunodeficiency virus 1 activity in vitro.

Authors:  T B McNeely; M Dealy; D J Dripps; J M Orenstein; S P Eisenberg; S M Wahl
Journal:  J Clin Invest       Date:  1995-07       Impact factor: 14.808

8.  Multiple components contribute to ability of saliva to inhibit influenza viruses.

Authors:  M R White; E J Helmerhorst; A Ligtenberg; M Karpel; T Tecle; W L Siqueira; F G Oppenheim; K L Hartshorn
Journal:  Oral Microbiol Immunol       Date:  2009-02

9.  Proline-rich tandem repeats of antibody complementarity-determining regions bind and neutralize human immunodeficiency virus type 1 particles.

Authors:  J D Fontenot; V R Zacharopoulos; D M Phillips
Journal:  J Virol       Date:  1996-10       Impact factor: 5.103

10.  Low copy number and limited variability of proviral DNA in alveolar macrophages from HIV-1-infected patients: evidence for genetic differences in HIV-1 between lung and blood macrophage populations.

Authors:  K Nakata; M Weiden; T Harkin; D Ho; W N Rom
Journal:  Mol Med       Date:  1995-11       Impact factor: 6.354

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.